Immune activity by radiofrequency ablation (RFA) in non-resected biliary tract cancer

JRCT ID: jRCT1050230099

Registered date:09/09/2023

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Biliary tract cancer
• Date of first enrollment: 09/09/2023
• Target sample size: 30
• Study type: Observational

Outcome(s)

• Primary Outcome: The expression levels of PD-1 , PD-L1, GAPDH, and CD8 genes in peripheral blood before and after RFA (1 day, 3 days, 1 week, and 14 days after treatment) will be measured and the gene levels will be observed.

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

Patients with biliary tract cancer with obstructive jaundice
Patients who need endoscopic biliary drainage and are scheduled for stenting
Patients over 20 years old
Patients with unresectable biliary tract cancer
Patients with performance status 2 or lower

Exclude criteria

Patients with bleeding tendency
Patients with difficulty in endoscopic insertion
Patients with difficulty in endoscopic biliary drainage
Patients who are unable to give consent.

Related Information

• Primary Sponsor: Kitano Masayuki